COMMUNIQUÉS West-GlobeNewswire

Remix Therapeutics to Present Phase 1 Data of REM-422 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Conference in Late-Breaking Oral Presentation
13/10/2025
Study Evaluates Antitumor Activity and Safety of REM-422, a First/Best-in-Class Small Molecule MYB mRNA Degrader, in Patients with Adenoid Cystic Carcinoma WATERTOWN, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Remix [...]
EUROBIO SCIENTIFIC : RAPPORT FINANCIER SEMESTRIEL AU 30 JUIN 2025
13/10/2025
EUROBIO SCIENTIFIC : RAPPORT FINANCIER SEMESTRIEL AU 30 JUIN 2025 Pièce jointe ES_Rapport_Financier_Semestriel_30062025_Final_Clean
EUROBIO SCIENTIFIC : MISE À DISPOSITION DU RAPPORT FINANCIER SEMESTRIEL 2025
13/10/2025
MISE À DISPOSITION DU RAPPORT FINANCIER SEMESTRIEL 2025 Paris, le 13 octobre 2025 – 18h30 Eurobio Scientific (FR0013240934, ALERS, éligible PEA-PME), groupe français leader dans le diagnostic médical in vitro de [...]
Avacta to Present First Dual Payload pre|CISION® Medicines Data at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets Symposium
13/10/2025
Groundbreaking oncology development with the first dual payload peptide drug conjugate platform, establishing Avacta as a leader in combination therapy innovation LONDON and PHILADELPHIA, Oct. 13, 2025 (GLOBE NEWSWIRE [...]
Press release: Transparency Notification from Shareholder
13/10/2025
Transparency Notification from Shareholder Ghent, Belgium – 13 October 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), a pioneer in the treatment of drug-resistant fluid [...]
Quanta Therapeutics Announces First Clinical Data Presentation for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
13/10/2025
RADNOR, Pa. and SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately-held clinical-stage biopharmaceutical company leading the development of innovative, oral therapeutics for [...]
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
13/10/2025
- Plenary session oral presentation: Friday, October 24 10:00 -11:40 a.m. ET - Poster presentation on preclinical evaluation of petosemtamab on cancer stem cells: Friday, October 24 12:30-4:00 p.m. ET UTRECHT, The [...]
EarlyHealth Group acquiert CYB3R, l’entreprise de cybersécurité à la croissance la plus rapide du Golfe
13/10/2025
DUBAÏ, Émirats arabes unis, 13 oct. 2025 (GLOBE NEWSWIRE) -- EarlyHealth Group, une société internationale du secteur des services pharmaceutiques et des solutions pour les sciences de la vie, a acquis une participation [...]
New Study Confirms Stress-Reduction Benefits of Natural Remedies’ Ashwa.30
13/10/2025
BANGALORE, India, Oct. 13, 2025 (GLOBE NEWSWIRE) -- A new study conducted by Clinical Research Australia reinforces the stress-reducing potential of Natural Remedies ’ Ashwa.30 , a next-generation ashwagandha extract. [...]
General Oncology to Present Preliminary Phase 1 Results from SHARON Trial in Patients with BRCA/PALB2-mutated Pancreatic and Breast Cancer at ESMO 2025
13/10/2025
BOSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- General Oncology, Inc. (“General Oncology” or the “Company”), a clinical-stage biopharmaceutical company dedicated to pioneering first-in-class medicines for metastatic cancers [...]
Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025
13/10/2025
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that complete data from the [...]
PacBio HiFi Technology Selected as Core Platform for South Korea’s National Pangenome Project
13/10/2025
More than 1,000 Korean genomes to be sequenced for global reference standards, advancing disease research and precision medicine MENLO PARK, Calif. and SEOUL, South Korea, Oct. 13, 2025 (GLOBE NEWSWIRE) -- PacBio ( [...]
MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes
13/10/2025
If approved, it would be the first needle-free insulin option for pediatric patients in 100+ years of insulin therapy sBLA submission based on data from the Phase 3 INHALE-1 study PDUFA target action date of May 29, [...]
Auron Therapeutics to Participate in the 8th Annual Targeted Protein Degradation & Induced Proximity Summit
13/10/2025
NEWTON, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today [...]
Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025
13/10/2025
Presentation will cover two-year clinical efficacy, immunogenicity and safety data Data will be presented at an oral session on October 17, 2025, followed by a webinar on October 22, 2025, providing further insights [...]
HMNC Brain Health Presents New Analysis Supporting Rationale for Combining a Genetic Patient Selection Tool with a Vasopressin V1b Receptor Antagonist in the Treatment of Depression at ISCTM Conference in Amsterdam
13/10/2025
Findings suggest a subset of Major Depressive Disorder patients may respond preferentially to vasopressin V1b receptor antagonism MUNICH, Oct. 13, 2025 (GLOBE NEWSWIRE) -- HMNC Brain Health, a clinical-stage precision [...]
Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing
13/10/2025
– Collegium to Ring Nasdaq Opening Bell on October 14, 2025 – STOUGHTON, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management team will ring the [...]
Hinge Bio Announces FDA Clearance of Investigational New Drug Application for HB2198, a Novel B cell-Depleting Agent, for Patients with Systemic Lupus Erythematosus and Lupus Nephritis
13/10/2025
Phase 1 trial to investigate novel multi-specific HB2198 to treat B cell-mediated autoimmune disorders by targeting both CD19 and CD20 plus enhanced immune cell engagement via dual Fc domains BURLINGAME, Calif., Oct. 13 [...]
SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025
13/10/2025
Preclinical data support SLS009 as a monotherapy or in combination with venetoclax for the treatment of T-PLL, a rare and highly aggressive form of mature T-cell leukemia NEW YORK, Oct. 13, 2025 (GLOBE NEWSWIRE) -- [...]

Pages